• Markets
    • icon
  • Companies
CYP · ASX

Cynata Therapeutics Limited (ASX:CYP)

AU$0.26

 0.005 (2.0%)
ASX:Live
26/07/2024 04:10:15 PM
HALO Ords HALO Consensus Value GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

CYP Overview

CYP Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About CYP

Website

Cynata Therapeutics Limited

Telephone

61.3.7067.6940

Address

Level 3 100 Cubitt Street Cremorne, Victoria (VIC) 3121

Description

Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. It focuses on proprietary mesenchymal stem cell technology. The company was founded on March 12, 2003 and is headquartered in Carlton, Australia.

CYP Price Chart

Key Stats

Market Cap

AU$44.91M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.1 - 0.34

Trade Value (12mth)

AU$5,002.00

1 week

-3.85%

1 month

-10.71%

YTD

108.33%

1 year

72.41%

All time high

4.60

Key Fundamentals

EPS 3 yr Growth

183.600%

EBITDA Margin

N/A

Operating Cashflow

-$14m

Free Cash Flow Return

-70.20%

ROIC

-70.20%

Interest Coverage

N/A

Quick Ratio

7.50

Other Data

Shares on Issue (Fully Dilluted)

180m

HALO Sector

Healthcare

Next Company Report Date

22-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

CYP Announcements

Latest Announcements

Date Announcements

19 July 24

Application for quotation of securities - CYP

×

Application for quotation of securities - CYP

12 July 24

Cynata Presents at Bioshares Summit

×

Cynata Presents at Bioshares Summit

01 July 24

Cynata to Acquire IP from Tekcyte

×

Cynata to Acquire IP from Tekcyte

01 July 24

Proposed issue of securities - CYP

×

Proposed issue of securities - CYP

27 June 24

Sharewise Investor Presentation

×

Sharewise Investor Presentation

29 May 24

CYP Presents at Major International Cell Therapy Conference

×

CYP Presents at Major International Cell Therapy Conference

22 May 24

Further GvHD Clinical Data Published in Nature Medicine

×

Further GvHD Clinical Data Published in Nature Medicine

17 May 24

Notification of cessation of securities - CYP

×

Notification of cessation of securities - CYP

17 May 24

Appendix 3Y-Dr Geoffrey Brooke

×

Appendix 3Y-Dr Geoffrey Brooke

07 May 24

Investor Presentation

×

Investor Presentation

30 April 24

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

17 April 24

Notification regarding unquoted securities - CYP

×

Notification regarding unquoted securities - CYP

08 April 24

DFU Clinical Trial Enrolment Complete

×

DFU Clinical Trial Enrolment Complete

20 March 24

EU Approval for Phase 2 CYP-001 Trial in GvHD

×

EU Approval for Phase 2 CYP-001 Trial in GvHD

18 March 24

Cynata Presenting at Advanced Therapies Congress

×

Cynata Presenting at Advanced Therapies Congress

05 March 24

First Patient Treated in Phase 2 GvHD Trial

×

First Patient Treated in Phase 2 GvHD Trial

29 February 24

Cynata Appoints New Chief Business Officer

×

Cynata Appoints New Chief Business Officer

26 February 24

Encouraging Initial Data from CYP-006TK DFU Trial

×

Encouraging Initial Data from CYP-006TK DFU Trial

23 February 24

Appendix 4D & Half-Year Financial Statements

×

Appendix 4D & Half-Year Financial Statements

30 January 24

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

16 January 24

Notification regarding unquoted securities - CYP

×

Notification regarding unquoted securities - CYP

28 December 23

Initial Results in First 16 DFU Patients Expected in Q1 2024

×

Initial Results in First 16 DFU Patients Expected in Q1 2024

13 December 23

Recruitment Completed in Phase 3 OA Clinical Trial

×

Recruitment Completed in Phase 3 OA Clinical Trial

07 December 23

Phase 2 Trial of CYP-001 in aGvHD Approved in Turkey

×

Phase 2 Trial of CYP-001 in aGvHD Approved in Turkey

23 November 23

Appendix 3Y - Dr Kilian Kelly

×

Appendix 3Y - Dr Kilian Kelly

CYP Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.06 -0.04 -0.10 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.06 -0.04 -0.10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -70.0 35.6 -158.9 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.04 -0.03 -0.08 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.04 -0.02 -0.10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -75.0 27.3 -152.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock -7.8 -6.4 -78.8 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.20 0.17 0.09 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.18 0.15 0.08 Lock Lock Lock
     Growth % Lock Lock Lock Lock 52.4 -16.1 -46.0 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 130 143 145 Lock Lock Lock
Basic m Lock Lock Lock Lock 130 143 145 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 9 14 16 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.3 0.0 0.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -9 -7 -16 Lock Lock Lock
     Growth % Lock Lock Lock Lock 14.0 24.8 -145.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -9 -7 -17 Lock Lock Lock
     Growth % Lock Lock Lock Lock 13.6 24.0 -139.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -9 -6 -16 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -1 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -8 -5 -14 Lock Lock Lock
     Growth % Lock Lock Lock Lock -111.3 29.2 -162.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -5 -3 -14 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 18 0 7 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -5 -3 -14 Lock Lock Lock
     Growth % Lock Lock Lock Lock -52.4 36.1 -333.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 27 24 16 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 30 27 19 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -27 -24 -16 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 3 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 28 24 17 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 28 24 17 Lock Lock Lock
     Growth % Lock Lock Lock Lock 69.0 -15.6 -30.2 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -25.7 -20.5 -75.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -27.1 -22.7 -85.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -40.2 -26.4 -81.3 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -34.1 -20.8 -70.2 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -22.9 -12.6 -70.2 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 3.0 3.6 1.0 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -94.2 -99.3 -96.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 17.0 9.3 7.5 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 17.0 9.3 7.5 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 97.9 98.6 95.9 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -322.3 -127.4 -631.9 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -25.7 -20.5 -75.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -27.1 -22.7 -85.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -27.1 -22.7 -85.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 634.6 1,471.2 1,883.4 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -634.6 -1,471.2 -1,883.4 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CYP Shortsell

Frequently Asked Questions

The current share price of Cynata Therapeutics Limited (CYP:ASX) is AU$0.26.
The 52-week high share price for Cynata Therapeutics Limited (CYP:ASX) is AU$0.34.
The 52-week low share price for Cynata Therapeutics Limited (CYP:ASX)? is AU$0.10.
Cynata Therapeutics Limited (CYP:ASX) does not pay a dividend.
Cynata Therapeutics Limited (CYP:ASX) does not pay a dividend.
Cynata Therapeutics Limited (CYP:ASX) has a franking level of 0.0%.
Cynata Therapeutics Limited (CYP:ASX) is classified in the Healthcare.
The current P/E ratio for Cynata Therapeutics Limited (CYP:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.